ASX - By Stock
|
BNO |
Re:
News: BNO Bionomics Reports Topline Results In Prevail Phase 2 Study Of BNC210
|
|
JamesTas
|
12 |
7.3K |
1 |
19/12/22 |
19/12/22 |
ASX - By Stock
|
12
|
7.3K
|
1
|
|
ASX - By Stock
|
BNO |
Re:
News: BNO Bionomics Reports Topline Results In Prevail Phase 2 Study Of BNC210
|
|
JamesTas
|
12 |
7.3K |
1 |
19/12/22 |
19/12/22 |
ASX - By Stock
|
12
|
7.3K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Mozz Research 2022
|
|
JamesTas
|
24 |
9.6K |
6 |
18/12/22 |
18/12/22 |
ASX - By Stock
|
24
|
9.6K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Change in substantial holding
|
|
JamesTas
|
22 |
8.8K |
13 |
16/12/22 |
16/12/22 |
ASX - By Stock
|
22
|
8.8K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
JamesTas
|
4.2K |
3.8M |
7 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm AGM Presentation
|
|
JamesTas
|
141 |
57K |
9 |
01/12/22 |
01/12/22 |
ASX - By Stock
|
141
|
57K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm CEO steps down & Appointment of MD
|
|
JamesTas
|
213 |
75K |
10 |
23/11/22 |
23/11/22 |
ASX - By Stock
|
213
|
75K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm CEO steps down & Appointment of MD
|
|
JamesTas
|
213 |
75K |
6 |
22/11/22 |
22/11/22 |
ASX - By Stock
|
213
|
75K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
JamesTas
|
4.2K |
3.8M |
3 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Bell Potter Health Care Conference
|
|
JamesTas
|
15 |
7.8K |
2 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
15
|
7.8K
|
2
|
|
ASX - By Stock
|
PAR |
Bell Potter Health Care Conference
|
|
JamesTas
|
15 |
7.8K |
26 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
15
|
7.8K
|
26
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
JamesTas
|
4.1K |
1.9M |
4 |
20/10/22 |
20/10/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Beech forests and climate change
|
|
JamesTas
|
1 |
776 |
5 |
19/10/22 |
19/10/22 |
ASX - By Stock
|
1
|
776
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
JamesTas
|
115 |
58K |
5 |
03/10/22 |
03/10/22 |
ASX - By Stock
|
115
|
58K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
JamesTas
|
115 |
58K |
3 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
115
|
58K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
5 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
104
|
40K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
7 |
29/09/22 |
29/09/22 |
ASX - By Stock
|
104
|
40K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
2 |
29/09/22 |
29/09/22 |
ASX - By Stock
|
104
|
40K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
5 |
27/09/22 |
27/09/22 |
ASX - By Stock
|
104
|
40K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
3 |
27/09/22 |
27/09/22 |
ASX - By Stock
|
104
|
40K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
13 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
JamesTas
|
104 |
40K |
5 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
PAR Broker Data
|
|
JamesTas
|
336 |
146K |
1 |
23/09/22 |
23/09/22 |
ASX - By Stock
|
336
|
146K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
JamesTas
|
4.2K |
3.8M |
4 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
5 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
109
|
39K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
4 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
109
|
39K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
PARate Day Share Price 2022
|
|
JamesTas
|
116 |
51K |
12 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
116
|
51K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
JamesTas
|
4.2K |
3.8M |
1 |
16/09/22 |
16/09/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
2 |
16/09/22 |
16/09/22 |
ASX - By Stock
|
109
|
39K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
2 |
14/09/22 |
14/09/22 |
ASX - By Stock
|
109
|
39K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
2 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
109
|
39K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
4 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
109
|
39K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
JamesTas
|
109 |
39K |
8 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
109
|
39K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
The Doctor Forum II - AF & FDA Round Table Discussion
|
|
JamesTas
|
29 |
12K |
8 |
10/09/22 |
10/09/22 |
ASX - By Stock
|
29
|
12K
|
8
|
|
ASX - By Stock
|
NSB |
Re:
Ann: CEO Resignation
|
|
JamesTas
|
28 |
12K |
0 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
28
|
12K
|
0
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Investor Update Webinar
|
|
JamesTas
|
51 |
15K |
2 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
51
|
15K
|
2
|
|
ASX - By Stock
|
NSB |
Re:
Ann: HREC decision to not approve Phase I Clinical Trial
|
|
JamesTas
|
96 |
38K |
1 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
96
|
38K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Launches $66M Capital Raising
|
|
JamesTas
|
132 |
56K |
7 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
132
|
56K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Launches $66M Capital Raising
|
|
JamesTas
|
132 |
56K |
3 |
31/08/22 |
31/08/22 |
ASX - By Stock
|
132
|
56K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Launches $66M Capital Raising
|
|
JamesTas
|
132 |
56K |
3 |
31/08/22 |
31/08/22 |
ASX - By Stock
|
132
|
56K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
JamesTas
|
4.1K |
1.9M |
3 |
30/08/22 |
30/08/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: 2022 Annual Report and Appendix 4E
|
|
JamesTas
|
26 |
10K |
3 |
26/08/22 |
26/08/22 |
ASX - By Stock
|
26
|
10K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: 2022 Annual Report and Appendix 4E
|
|
JamesTas
|
26 |
10K |
1 |
26/08/22 |
26/08/22 |
ASX - By Stock
|
26
|
10K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Entitlement Offer Confusion
|
|
JamesTas
|
2 |
939 |
1 |
23/08/22 |
23/08/22 |
ASX - By Stock
|
2
|
939
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Doses First US Subjects under Phase 3 trial
|
|
JamesTas
|
58 |
24K |
5 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
58
|
24K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
JamesTas
|
276 |
107K |
10 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
276
|
107K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Presentation - $66m Capital Raise
|
|
JamesTas
|
87 |
35K |
1 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
87
|
35K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Presentation - $66m Capital Raise
|
|
JamesTas
|
87 |
35K |
6 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
87
|
35K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
2b or NOT to be
|
|
JamesTas
|
84 |
30K |
1 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
84
|
30K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
2b or NOT to be
|
|
JamesTas
|
84 |
30K |
4 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
84
|
30K
|
4
|
|